Stifel Nicolaus Sticks to Its Buy Rating for Disc Medicine (IRON)
In a report released today, Stephen Willey from Stifel Nicolaus maintained a Buy rating on Disc Medicine, with a price target of $110.00.
President's Day Sale - 70% Off
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
According to TipRanks, Willey is a 4-star analyst with an average return of 7.2% and a 41.56% success rate. Willey covers the Healthcare sector, focusing on stocks such as Disc Medicine, Exelixis, and Nurix Therapeutics.
In addition to Stifel Nicolaus, Disc Medicine also received a Buy from H.C. Wainwright’s Douglas Tsao in a report issued today. However, on February 4, TipRanks – Google reiterated a Hold rating on Disc Medicine (NASDAQ: IRON).
Based on Disc Medicine’s latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $62.32 million. In comparison, last year the company had a GAAP net loss of $26.6 million
Based on the recent corporate insider activity of 54 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of IRON in relation to earlier this year. Most recently, in December 2025, Kevin Bitterman, a Director at IRON sold 754.00 shares for a total of $68,968.38.
Read More on IRON:
Disclaimer & DisclosureReport an Issue
- Disc Medicine: Long‑Term Value Intact as Bitopertin Shifts to Lower‑Risk Traditional Approval Path
- Disc Medicine move down Friday ‘fair’ after bitopertin CRL, says Wells Fargo
- Disc Medicine Receives FDA Complete Response on Bitopertin
- Disc Medicine off lows after saying FDA issue ‘readily addressable’
- Disc Medicine down 32% to $49 after confirming rejection letter from FDA
